Herceptin (trastuzumab) / Roche - LARVOL DELTA

Cardioprotection without risk? meta-analysis of prophylactic agents in low-risk cancer patients on anthracyclines (ASH 2025) - "We included randomized controlled trials (RCTs) of prophylactic ACE inhibitors, ARBs, beta-blockers, statins, dexrazoxane, or SGLT2 inhibitors in adults without pre-existing cardiovascular risk factors...Agents studied included beta-blockers (nebivolol, carvedilol, bisoprolol), ACE inhibitors (ramipril), ARBs (telmisartan), and spironolactone. Treatment duration ranged from 4 months to 1 year; anthracycline doses reached up to 689 mg/m² (epirubicin) or 536 mg/m² (doxorubicin)...The protective benefit was greater in contexts involving higher cumulative anthracycline doses and concurrent cardiotoxic therapies such as trastuzumab...However, high heterogeneity limits firm conclusions. Given the moderate effect size and heterogeneity, further large-scale, well-formulated trials are essential to identify optimal cardioprotective agents and precise patient selection criteria."

Retrospective data • Breast Cancer • Congestive Heart Failure • Heart Failure • Oncology • Solid Tumor

Distinguishing on-target efficacy and off-target toxicity with antibody drug conjugates (ADCs) on diseased and normal hematopoietic cells (ASH 2025) - "Therefore, many ADCs, for example Trastuzumab-vc-MMAE (Enhertu) targeting specific diseased proteins (HER-2) which are not present on hematopoietic cells, may still have hematopoietic liabilities. Although this value was significantly different to that of Mylotarg on normal marrow progenitors, off-target toxicity was demonstrated. These data suggest that clonal assays with primary normal and diseased bone marrow cells may provide insight as to relative potency of an ADC on a disease-specific target as well as potential off-target toxicity to normal hematopoietic progenitors."

Clinical • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Thrombocytopenia • CD33 • HER-2 • PTPRC

A nyelőcső-, GEJ- és gyomordaganatok immunterápiája. (PubMed, Magy Onkol) - "In esophageal tumors, adjuvant nivolumab is used. Among HER2-positive patients, adding pembrolizumab to trastuzumab and chemotherapy - in PDL1 CPS ≥1 cases - has become a new standard. A special mention must be made of MSI-H tumors, in which immunotherapy is highly effective, and adjuvant chemotherapy is not recommended according to current guidelines."

Journal • Review • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Microsatellite Instability • Oncology • Solid Tumor • HER-2 • MSI

Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma (ASH 2025) - "Monoclonal antibodies (mAbs), which function toactivate immune cells against target cells, have been extensively explored for the treatment of MM.Daratumumab (Dara), an FDA-approved anti-CD38 mAb, has significantly increased the lifespan of MMpatients; however, most patients inevitably develop resistance...Additionally, Trastuzumab(Tras), which targets an antigen not expressed on MM cells, had no killing activity when conjugated toMMAF...The targeteddelivery of a toxic payload represents an orthogonal approach to current treatment options for RRMM.These preclinical data establish that mAb 1 has enhanced efficacy compared to Dara when used as anADC, which can be attributed to its distinct kinetics and binding epitope. This strategy addresses a criticalunmet need and may represent a valuable addition to the evolving treatment landscape for RRMM."

IO biomarker • Hematological Malignancies • Multiple Myeloma

Neoadjuvant HLX11 versus European Union (EU)-sourced pertuzumab in human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-negative early or locally advanced, breast cancer (BC): A double-blind, randomised phase III equivalence study (ESMO Asia 2025) - P3 | "Enrolled patients were randomised 1:1 to receive 4 cycles of intravenous (IV) HLX11 (HLX11 arm) or reference pertuzumab (EU-pertuzumab arm) plus trastuzumab and docetaxel every 3 weeks (Q3W). HLX11 showed equivalent efficacy and comparable safety, immunogenicity and PK to the EU-sourced pertuzumab, supporting HLX11 as a potential pertuzumab biosimilar."

Clinical • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • HER-2

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of Asian patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): A DESTINY-Breast09 analysis (ESMO Asia 2025) - P3 | "T-DXd + P demonstrated consistent efficacy as 1L treatment in Asian pts with HER2+ a/mBC, with no new safety signals. Table: 88MO Data in brackets are 95% CIs. *Estimate may change at updated analysis BICR, blinded independent central review; CI, confidence interval; DOR, duration of response; INV, investigator; mo, months; NC, not calculable; PFS, progression-free survival; ORR, objective response rate"

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA

Disparities in access to targeted therapy and immunotherapy in southeast Asia: A systematic review of policy and practice gaps (ESMO Asia 2025) - "In Thailand, access to trastuzumab and EGFR-TKIs was markedly unequal among different insurance schemes, with patients under Universal Health Coverage receiving more limited support... The limited number of eligible studies reflects a broader evidence gap in regional health equity research, underscoring the need for further investigation to inform inclusive cancer policy across Southeast Asia."

Review • Oncology

BNT323-01: A phase III trial of trastuzumab pamirtecan (HER2 ADC) versus investigator's choice of chemotherapy in pretreated patients with HER2-expressing recurrent endometrial cancer (EC) (ESMO Asia 2025) - P1/2, P3 | "Approximately 504 pts with previously treated HER2-expressing EC will be randomized 2:1 to receive T-Pam IV every 3 weeks, or physicians' choice chemotherapy (doxorubicin or weekly paclitaxel) until RECIST v1.1-defined progressive disease, unacceptable toxicity, or withdrawal of consent. Secondary endpoints are PFS by BICR in all pts, overall survival (OS), PFS by investigator, ORR, duration of response, and safety. Enrollment has been initiated at several sites globally."

Clinical • IO biomarker • P3 data • Endometrial Cancer • Oncology • Solid Tumor • HER-2

Identification of potential immune biomarkers associating to clinical benefit from intensive chemotherapy combined with serplulimab and trastuzumab in advanced HER2+ gastric cancer: A post-hoc analysis of the ASTRUM study (ESMO Asia 2025) - P2 | "Expolatoring immune biomarkers is essential for patients' straitification and optimizing therapeutic strategy. 40 pts enrolled from July 2022 to September 2024 received S (4.5 mg/kg, D1, Q3W), T (initial 8 mg/kg, D1, then 6 mg/kg, D1, Q3W), and DOS chemotherapy (oxaliplatin 100 mg/m2, docetaxel 40 mg/m2 IV, S-1 40–60 mg BID D1–14 Q3W)... Integrated tumour and circulating immune signatures forecast durable efficacy of treatment. baseline immune biomarkers serve as putatively predictive biomarkers for clinical benefit."

Biomarker • Clinical • IO biomarker • Metastases • Retrospective data • Gastric Cancer • Oncology • Solid Tumor • CCL19 • CD22 • CD8 • CD86 • CRTAM • HER-2 • IL6 • KDR • MMP1 • PGF • TNFRSF18 • XCL2 • ZAP70

Updated outcome and ctDNA profiling in advanced HER2+ gastric cancer patients treated with DOS plus serplulimab and trastuzumab: A phase II multicenter trial (ESMO Asia 2025) - P2 | "DOS with plus S and T displayed sustained anti-tumor activity. ctDNA dynamics, especially blood ERBB2 CN hold substantial clinical utility for evaluating clinical outcomes in advanced HER2+ gastric cancer."

Circulating tumor DNA • Clinical • IO biomarker • Metastases • P2 data • Tumor mutational burden • Gastric Cancer • Oncology • Solid Tumor • HER-2 • TMB

Preliminary efficacy and safety of TQB2102 in HER2-positive locally advanced unresectable or metastatic biliary tract cancer: Phase Ib study results (ESMO Asia 2025) - P1/2 | "Notably, in Cohort 1, the ORR was 28.6% (95% CI: 3.7–71.0) in pts with prior anti-HER2 therapy( Trastuzumab,Pertuzumab,DS-8201) and 50% (95% CI: 6.8–93.2) in HER2 IHC 2+ and ISH+ pts. TQB2102 demonstrated favorable tolerability and encouraging antitumor activity in HER2-positive locally advanced/metastatic BTC. The 7.5 mg/kg dose showed superior efficacy versus 6.0 mg/kg and is therefore recommended as the RP2D for BTC. The Phase 2 study is currently in preparation."

Clinical • Metastases • P1 data • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor • CD4 • HER-2

Clinical efficacy and safety of genexol PM in patients with solid tumours: A retrospective observational study in Indian patients (ESMO Asia 2025) - "Paclitaxel monotherapy was given in 23.7%...Bevacizumab (n=15) was the most used targeted therapy followed by Trastuzumab (n=6) and Ramucirumab (n=5)... These results suggest that Genexol PM cremophor-free formulation is a promising approach in multiple solid malignancies and generally well tolerated among Indian patients."

Observational data • Retrospective data • Breast Cancer • Cervical Cancer • Gynecologic Cancers • Head and Neck Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Cross-cancer transcriptomic landscape of HER2-positive tumors and associations with trastuzumab resistance (ESMO Asia 2025) - "A conserved three-gene module appears central to HER2-driven oncogenesis across BC, GC and CRC, but divergent pathway and immune landscapes likely modulate therapeutic response to anti-HER2 treatment. These findings support tumour-type-specific strategies, such as MTOR inhibitors in GC, or immune-modulating agents in GC and CRC, to enhance the effectiveness of HER2-targeted treatments."

Breast Cancer • Colorectal Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • GRB7 • HER-2 • MIEN1

HydroLock: A versatile ADC platform with robust plasma stability, excellent bystander killing and superior in vivo efficacy (ESMO Asia 2025) - "Efficacies of Herceptin-GSC4903 and the potential to overcome DS8201 resistance were determined...We also conjugate eribulin to pertuzumab (Pertuzumab-GSC4781)... All these results warrant HydroLock as a novel and promising linker-payload platform for ADC development. HydroLock was leveraged in several bispecific ADC programs and the first IND submission is expected in late 2025."

Preclinical • Oncology

Efficacy and safety of lapatinib in comparison with trastuzumab therapy for HER2-positive advanced and metastatic breast cancer (ESMO Asia 2025) - "This meta-analysis indicates that Trastuzumab remains superior to Lapatinib in terms of OS and PFS for patients with advanced and metastatic HER2-positive breast cancer. Although Lapatinib shows a comparable safety profile with no significant increase in severe adverse events, its efficacy is inferior to Trastuzumab. These findings support the continued use of Trastuzumab as the preferred first-line therapy in this setting."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Pertuzumab versus pyrotinib in combination with trastuzumab and taxanes for first-line (1L) treatment of patients with HER2–positive metastatic breast cancer (HER2+MBC): A multicenter real-world study (ESMO Asia 2025) - "Background: The CLEOPATRA study established taxane+trastuzumab+pertuzumab(THP)as the 1L standard for HER2+ MBC over a decade ago. The recent PHILA study showed that docetaxel+trastuzumab+pyrotinib (an irreversible pan-HER receptor tyrosine kinase inhibitor ) (THPy) significantly prolonged progression-free survival (PFS)versus placebo group, establishing it as a viable 1L option in China.Given limited comparative evidence, this real-world study aimed to evaluate the effectiveness of THP and THPy in HER2+ MBC patients and identify potential beneficiary populations for each regimen. Patients who were treated with THP or THPy as a 1L treatment between January 2018 and March 2025 were included in this multicenter real-world study... Compared with the THP ,THPy significantly improved PFS in patients with untreated HER2+MBC. Notably, THPy demonstrated superior survival benefits specifically in subgroups with:premenopausal status, ECOG PS 0, de novo stage IV disease, previous..."

Clinical • Combination therapy • Metastases • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

HKB99 enhances sensitivity of HER2-positive breast cancer to trastuzumab by disrupting bipolar spindle formation (ESMO Asia 2025) - "These findings unveil a novel mechanism for HKB99 and offer a promising strategy to overcome trastuzumab resistance."

Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PGAM1 • TUBA1B

Trastuzumab in small, node-negative (T1N0) HER2-positive breast cancer: Unveiling efficacy and utilization (ESMO Asia 2025) - "In this cohort, patients with small, node-negative HER2-positive breast cancer achieved excellent long-term survival outcomes. Although adjuvant trastuzumab remains the standard of care, our findings suggest that excellent survival can be achieved in selected patients. Careful risk assessment is essential when considering treatment strategies, and further prospective studies are needed to better define optimal management for this population."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Impact of neoadjuvant TCHP dose intensity on pathological complete response in early HER2+ breast cancer: A Saudi retrospective study (ESMO Asia 2025) - "This study evaluated the impact of neoadjuvant TCHP DI (docetaxel, carboplatin, trastuzumab, pertuzumab) on pCR in early-stage HER2-positive breast cancer...Switching to paclitaxel showed a non-significant reduction in pCR (OR 0.26; p=0.107). DI reductions were common... DI reductions were common. While DI ≥0.85 was associated with numerically higher pCR, only carboplatin DI independently predicted pCR. HR positivity and docetaxel substitution were linked to lower pCR odds."

Retrospective data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Encapsulation-based enhancements in modern drug delivery systems. (PubMed, Int J Pharm) - "In addition, the pharmaceutical industry has commercialized many encapsulated drugs, such as anti-inflammatory (ibuprofen, dexamethasone), high blood pressure drugs (valsartan, azilsartan), proton pump inhibitors (lansoprazole), anti-cancer (carboplatin, carmustine, cisplatin, trastuzumab, cytarabine, paclitaxel, doxorubicin (DOX), vincristine) antiparasitic (amphotericin), antifungal (clotrimazole), and hormonal (melatonin (MLT))). It can render drugs more convenient and user-friendly for various therapeutic purposes and help to enhance their performance, functionality, and effectiveness. This comprehensive review examines the encapsulation technologies employed in the pharmaceutical industry, highlighting notable examples of encapsulated drugs that demonstrate their mechanism of action and potential therapeutic effects in vitro, in vivo, and through clinical trials, with relevance to various diseases."

Journal • Review • Cardiovascular • Hypertension • Oncology

Glycan profiling of therapeutic monoclonal antibodies: Rapid, non-denaturing single-step digestion via pH-tuned enzymatic cleavage. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "Validation with trastuzumab (IgG1) and sintilimab (IgG4) showed nearly identical N-glycan profiles to conventional methods, retaining chromatographic properties and yielding comparable FA2 peak areas and glycoform abundances. MS revealed consistent glycoform profiles between methods (27 vs. 25 glycoforms in optimized vs. conventional), with strong abundance correlation. These results demonstrate that the method is not only applicable to multi-sample scenarios but also fully MS compatible, offering a robust tool for biopharmaceutical development, batch consistency assessments, and biomarker discovery in glycobiology research."

Journal

The toxic effects of doxorubicin and trastuzumab on cardiac metabolic reprogramming are associated with impaired mitochondrial dynamics balance. (PubMed, Food Chem Toxicol) - "These novel findings highlighted the toxic effects of doxorubicin and trastuzumab on cardiac metabolic reprogramming and their association with mitochondrial dynamics. Also, metabolomics might be used as a tool for treatment monitoring in doxorubicin- and trastuzumab-induced cardiotoxicity."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

KEYNOTE 811: Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) (clinicaltrials.gov) - P3 | N=738 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

The PHERGuide study demonstrates the utility of circulating tumor DNA for the early detection and real-time monitoring of localized HER2+ breast cancer (PRNewswire) - "With more than 250 samples analyzed, the results show a direct association between the levels of ctDNA in blood at the start of the study and the stage of the disease. Furthermore, this study also reveals a significant correlation between ctDNA and the response to treatment. After two cycles of therapy, an elimination of ctDNA was observed in 75% of the patients; before surgery, these values reached a negativization of 83%."

P2 data • HER2 Positive Breast Cancer

Phase I trial of emavusertib (CA-4948) in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated, unresectable gastric and esophageal cancer. (ASCO-GI 2026) - P1 | "Funded by V Foundation Clinical Trial Registration Number: NCT05187182 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Combination therapy • P1 data • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology